Compounded Semaglutide vs Semaglutide
A side-by-side research comparison of Compounded Semaglutide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Compounded Semaglutide | Semaglutide |
|---|---|---|
| Full name | Compounded Semaglutide (503B Pharmacy) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | FDA Approved |
| Mechanism | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 4113.58 Da | 4,114 Da |
| Half-life | ~7 days | 7 days (168 hours) |
| Bioavailability | ~89% subcutaneous | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 0.25-2.4 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.